Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05433584 · ClinicalTrials.gov registry record · Phase 4

A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

A Phase 4 study of Type 2 Diabetes, sponsored by Eli Lilly and Company.

Active
Registry status
Phase 4
Development phase
780
Enrollment target
20
Study locations

NCT05433584 is a Phase 4 study of Type 2 Diabetes that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 780 participants, below the 1,100-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05433584, a Phase 4 study of Type 2 Diabetes, is active but no longer recruiting, sponsored by Eli Lilly and Company.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
780 participants
Enrollment target
20
Study locations

Study Summary

This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.

Conditions Studied

Type 2 Diabetes

Interventions

  • DRUG Tirzepatide
  • DRUG Antihyperglycemic medication

Study Locations (20)

California

  • San Fernando Valley Health Institute - Canoga Park
  • Velocity Clinical Research, Huntington Park - Huntington Park
  • Velocity Clinical Research, San Diego - La Mesa
  • Clinical Trials Research - Lincoln
  • Velocity Clinical Research, Westlake - Los Angeles
  • Catalina Research Institute, LLC - Montclair
  • Velocity Clinical Research, North Hollywood - North Hollywood
  • Velocity Clinical Research, Panorama City - Panorama City
  • Western University of Health Sciences - Pomona
  • Velocity Clinical Research, Santa Ana - Santa Ana

Florida

  • Excel Medical Clinical Trials - Boca Raton
  • Alliance for Multispecialty Research, LLC - Coral Gables
  • South Florida Clinical Research Institute - Margate

Georgia

  • Emory University School of Medicine- Grady Campus - Atlanta
  • Center for Advanced Research & Education - Gainesville

Alabama

  • Cahaba Research - Trussville - Birmingham

Connecticut

  • New England Research Associates, LLC - Bridgeport

Indiana

  • Qualmedica Research, LLC - Evansville

Iowa

  • Iowa Diabetes and Endocrinology Research Center - West Des Moines

Kentucky

  • Qualmedica Research - Bowling Green

Trial Details

FieldValue
Enrollment Target 780 participants
Start Date 2022-08-01
Est. Completion 2027-11
Phase Phase 4

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05433584

The ClinicalTrials.gov registry entry for NCT05433584 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 780 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,100-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (29% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Tirzepatide is the first listed.

NCT05433584 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT05433584 about?

NCT05433584 is a clinical study titled "A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes". This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.

What is the current status of trial NCT05433584?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 780 participants. The study started on 2022-08-01. Estimated completion is 2027-11.

What conditions does trial NCT05433584 study?

This clinical trial studies the following conditions: Type 2 Diabetes.

What interventions are being tested in trial NCT05433584?

The interventions under investigation include: Tirzepatide (DRUG), Antihyperglycemic medication (DRUG).

Who is sponsoring clinical trial NCT05433584?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05433584 being conducted?

This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.